Association study between clinical response to rizatriptan and some candidate genes

scientific article

Association study between clinical response to rizatriptan and some candidate genes is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S10194-007-0388-5
P932PMC publication ID3476140
P698PubMed publication ID17563839
P5875ResearchGate publication ID6272862

P50authorMaria Del ZompoQ43303007
Donatella CongiuQ43303034
P2093author name stringCarlo Asuni
Allesandra Cherchi
Maria E Stochino
Maria P Piccardi
P2860cites workHuman monoamine oxidase A gene determines levels of enzyme activityQ24678322
Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patientsQ28274131
Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory regionQ28297391
A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophreniaQ28307335
The impact of pharmacogenetics for migraineQ31925619
Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trialsQ34647375
Therapeutic implications of central and peripheral neurologic mechanisms in migraineQ35569301
Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response.Q39461967
Dopamine and migraineQ41598488
The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factorQ43592479
Mapping of the serotonin 5-HT1D beta autoreceptor gene on chromosome 6 and direct analysis for sequence variants.Q52208892
Direct sequencing of the dopamine D2 receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural change in the receptorQ55049552
Monte Carlo tests for associations between disease and alleles at highly polymorphic lociQ60627367
Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vesselsQ73230740
Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI allelesQ73508519
Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trialQ73883809
5-HT1B receptor polymorphism and clinical response to sumatriptanQ74574599
Neurogenic control of the cerebral microcirculation: is dopamine minding the store?Q77295945
Association between dopamine receptor genes and migraine without aura in a Sardinian sampleQ77332492
P433issue3
P304page(s)185-189
P577publication date2007-06-11
P1433published inThe journal of headache and pain : official journal of the Italian Society for the Study of HeadachesQ26842211
P1476titleAssociation study between clinical response to rizatriptan and some candidate genes
P478volume8

Reverse relations

cites work (P2860)
Q48226245Association of RAMP1 rs7590387 with the risk of migraine transformation into medication overuse headache
Q38108482Dopaminergic symptoms in migraine
Q36261201Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine
Q37818258Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy
Q35563650Genetic Polymorphisms in the Dopamine Receptor 2 Predict Acute Pain Severity after Motor Vehicle Collision
Q44921069Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility
Q84979035Migraine general aspects
Q39720265Negative predictors of clinical response to triptans in patients with migraine
Q44613289New genetic evidence for involvement of the dopamine system in migraine with aura
Q37064080Pharmacogenomics and migraine: possible implications
Q38195629Pharmacogenomics of episodic migraine: time has come for a step forward.
Q44739665Refractory migraine and chronic migraine: pathophysiological mechanisms
Q38096945Triptan nonresponders: do they exist and who are they?